| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
|
| | Caspase-9 Inhibitor Basic information |
| | Caspase-9 Inhibitor Chemical Properties |
| storage temp. | Store at -20°C | | Water Solubility | Water: 100 mg/mL (124.26 mM); |
| | Caspase-9 Inhibitor Usage And Synthesis |
| Uses | Z-LEHD-FMK TFA is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK TFA exhibits the neuroprotective effect in a rat model of spinal cord trauma[1][2][3]. | | in vivo | Z-LEHD-FMK (0.8 μmol/kg; i.v. for 7 d) protects neurons, glia, myelin, axons, and intracellular organelles in spinal cord injury (SCI) rats[2]. | Animal Model: | Male Wistar albino rats (250-350 g) with SCI[2] | | Dosage: | 0.8 μmol/kg | | Administration: | I.v. for 1 or 7 days | | Result: | Decreased the mean apoptotic cell count at 24 hours and 7 days postinjury. |
| | IC 50 | Caspase-9 | | References | [1] Ozoren N, et, al. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000 Nov 15; 60(22): 6259-65. PMID:11103780
[2] Colak A, et, al. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine. 2005 Mar; 2(3): 327-34. DOI:10.3171/spi.2005.2.3.0327
[3] Mocanu MM, et, al. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000 May; 130(2): 197-200. DOI:10.1038/sj.bjp.0703336 |
| | Caspase-9 Inhibitor Preparation Products And Raw materials |
|